DONG-A ST CO.,LTD Logo

DONG-A ST CO.,LTD

Develops and distributes ethical drugs, medical devices, and diagnostics for global healthcare.

170900 | KO

Overview

Corporate Details

ISIN(s):
KR7170900005
LEI:
Country:
South Korea
Address:
서울 동대문구 용두동 138 ~255 천호대로 64, 서울
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Dong-A ST Co., Ltd. is a specialized pharmaceutical and medical device company that spun off from Dong-A Socio Group in 2013. The company focuses on the development, manufacturing, and global distribution of ethical drugs (ETC), medical devices, and diagnostics. Its pharmaceutical portfolio includes domestically developed new drugs such as Stillen and Zydena, biopharmaceuticals, and chemical drugs. Dong-A ST is also a major global manufacturer of the tuberculosis API, Cycloserine. The medical device and diagnostics division provides comprehensive healthcare solutions in areas including ENT (Ear, Nose, Throat) equipment, in-vitro diagnostics, and infection control systems. With a strong emphasis on research and development, the company actively pursues international expansion through global partnerships and exports.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-09 00:00
Prospectus
투자설명서
Korean 2.8 MB
2025-09-09 00:00
Share Issue/Capital Change
증권발행실적보고서
Korean 47.8 KB
2025-09-08 00:00
Registration Form
[발행조건확정]증권신고서(채무증권)
Korean 14.6 KB
2025-09-03 00:00
Registration Form
[기재정정]증권신고서(채무증권)
Korean 3.1 MB
2025-09-03 00:00
Prospectus
[발행조건확정]증권신고서(채무증권)
Korean 275.8 KB
2025-08-28 00:00
Registration Form
증권신고서(채무증권)
Korean 2.8 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 3.3 MB
2025-08-13 00:00
Earnings Release
[기재정정]영업(잠정)실적(공정공시)
Korean 18.0 KB
2025-07-25 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 239.2 KB
2025-07-24 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 13.8 KB
2025-07-24 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.6 KB
2025-07-18 00:00
Report Publication Announcement
결산실적공시예고(안내공시)
Korean 4.1 KB
2025-07-18 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.8 KB
2025-07-07 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 61.5 KB
2025-07-07 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.7 KB

Automate Your Workflow. Get a real-time feed of all DONG-A ST CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DONG-A ST CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DONG-A ST CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.